Jun 08, 2021 / 12:50PM GMT
Graig Suvannavejh - Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Good morning, everyone. Welcome to the 8:50 a.m. session of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh, and I cover both U.S. and European biopharma names here at Goldman Sachs.
It's my pleasure to be hosting DBV Technologies in a fireside chat this morning. And with that, let me welcome CEO, Daniel Tassé. Daniel, it's good to see you, again, and hope everything is well?
Daniel Tassé,DBV Technologies S.A.-CEO&Director
Thank you, Graig. Thank you. Yes, everything is wonderful. And thanks for having me this morning.
Graig Suvannavejh - Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Great. I think maybe just to start off with, it's always good to reset. And just for those who perhaps are newer to the DBV story or perhaps revisiting
DBV Technologies SA at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
